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Abstract: Classical swine fever virus (CSFV) remains a challenge for the porcine industry. Inefficient
vaccination programs in some endemic areas may have contributed to the emergence of low and
moderate virulence CSFV variants. This work aimed to expand and update the information about the
safety and efficacy of the CSFV Thiverval-strain vaccine. Two groups of pigs were vaccinated, and
a contact and control groups were also included. Animals were challenged with a highly virulent
CSFV strain at 21- or 5-days post vaccination (dpv). The vaccine induced rapid and strong IFN-α
response, mainly in the 5-day immunized group, and no vaccine virus transmission was detected.
Vaccinated pigs showed humoral response against CSFV E2 and Erns glycoproteins, with neutralising
activity, starting at 14 days post vaccination (dpv). Strong clinical protection was afforded in all the
vaccinated pigs as early as 5 dpv. The vaccine controlled viral replication after challenge, showing
efficient virological protection in the 21-day immunized pigs despite being housed with animals
excreting high CSFV titres. These results demonstrate the high efficacy of the Thiverval strain against
CSFV replication. Its early protection capacity makes it a useful alternative for emergency vaccination
and a consistent tool for CSFV control worldwide.
Keywords: CSFV; vaccination; vaccine; Thiverval strain; immune response; clinical protection;
virological protection; challenge
1. Introduction
Classical swine fever (CSF) is a highly contagious disease that affects domestic pigs
and wild boars. CSF poses a threat for the pig industry from sanitary and economic points
of view, and its notification is mandatory to the World Health Organization for animal
health (OIE) [1–3].
The CSF aetiological agent is the CSF virus (CSFV), an enveloped, single, positive-
stranded RNA virus within the Pestivirus genus into the Flaviviridae family. The viral
genome, of around 12.3 Kb of length, codifies for a unique polyprotein that after proteolytic
processing yields mature non-structural and structural proteins [4,5]. Among the latter, E2
and Erns glycoproteins are the main targets for neutralising antibodies [6].
Nowadays, the disease has been successfully eradicated in North America, Oceania,
and a large part of the European Union [7]. However, despite the implementation of
extensive eradication programs, CSF remains endemic in Asia, South and Central America,
and the Caribbean [7]. The risk for CSFV re-emergence remains high, as shown by the
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recent outbreaks in countries including Korea, Colombia, Russia, Brazil, and even Japan,
some of which had been CSF-free for decades [8,9].
Response policy to notification of an outbreak differs among different countries and
depends on each particular situation [10]. The European Union followed a non-vaccination
policy, accompanied by culling of infected animals and severe trade restrictions in the
way to successful eradication of the disease. However, this approach carries significant
ethical and economic implications. Meanwhile, in other countries where the virus remains
endemic, vaccination poses a sustainable alternative to prevent massive losses and to
contain the virus spread [2].
Modified live vaccines (MLVs) based on several attenuated virus strains, for example,
C-strain, Thiverval, PAV-250, GPE-, and K-strain, are widely used [3,11]. The C-strain based
vaccines are the most well studied ones, and their administration has proven to be safe and
highly effective regardless of the genotype of the challenge strain [12]. However, CSFV
persists in endemic countries even after active vaccination programs with these vaccines,
mainly in areas that use either cell-culture or lapinized C-strain [2]. It is likely that this
phenomenon is related to shortcomings in the vaccine program implementation rather than
the effectiveness of the vaccines themselves [13]. Moreover, it has been hypothesized that
this problem may have led to the emergence of new CSFV strains with low and moderate
virulence that have been associated with chronic and persistent forms of CSF that hinder
disease control [2].
The Thiverval vaccine, recommended in the OIE Manual for vaccination against
CSFV [14], has shown high efficacy against the disease. However, the information available
dates back to the 1970s and relies on techniques that are not up to date [15,16]. In addition,
its capacity to confer early protection after single vaccination has not been evaluated.
The aim of the present study was to update the existing information on the efficacy
of the Thiverval vaccine against CSFV at 21 days after a single inoculation, as well as its
early protection capacity at five days after vaccination. The immune response generated
after vaccination was evaluated. A contact group was included to assess the absence of
vaccine virus transmission from the vaccinated animals. Likewise, the clinical, virological,
and immunological protection afforded by the vaccine against a severe CSFV challenge
was determined, using currently validated techniques.
2. Materials and Methods
2.1. Cells and Viruses
Pestivirus-free porcine kidney cell line PK-15 ATCC (CCL-33) cells were grown in
Eagle’s minimum essential medium and supplemented with 5% fetal calf serum and used
for viral production, titration, and neutralization assays. The commercially available
Thiverval-strain vaccine (Coglapest®, CEVA, Santé Animale, France), (genotype 1.1) was
used for vaccination in the in vivo assay. The highly virulent CSFV Margarita strain
(genotype 1.4), which generates the lethal CSF form, was also employed [17]. The CSFV
strain Alfort/187 was kindly provided by the CSFV EU Reference Laboratory (EURL),
Hannover, Germany. The immune peroxidase monolayer assay (IPMA) with a swine
polyclonal Pestivirus antibody was used to assess the viral replication [18], and viral titres
were determined by endpoint dilution. The 50% tissue culture infective dose (TCID50) per
millilitre was calculated using statistical methods previously described [19].
2.2. Experimental Design
Six-week-old piglets (n = 23), purchased from a commercial Spanish Pestivirus-free
farm, were allocated in the animal biosafety level 3 (ABSL3) facility at IRTA-CReSA
(Barcelona, Spain). Animals were numbered and divided randomly in four groups: groups
A (pigs 1 to 7), B (pigs 8 to 13), C (pigs 14 to 18), and D (pigs 19 to 23). After the ac-
climatization period, group A was vaccinated with 2 mL (4 × 103 plaque forming units
(PFU)) of Thiverval strain through intramuscular injection in the neck, according to the
manufacturer’s instructions. Group B pigs were inoculated with sterile PBS and were
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housed together with group A, serving as contacts to monitor the transmission capacity of
the vaccine virus. Sixteen days after vaccination of group A, animals from group C were
vaccinated with the Thiverval strain, following the same volume and dose of group A pigs.
Finally, the group D were used as infection controls, being inoculated with PBS.
To evaluate the vaccine virus transmission and replication in tissues, at 21 dpv one
animal from group A and two from group B were euthanized, and tonsil, thymus, spleen,
and mesenteric lymph node samples were collected. At this time, at 21 dpv and 5 dpv
for groups A and C, respectively, all the pigs from the four experimental groups were
challenged by intramuscular injection in the right neck with 105 TCID of CSFV Margarita
strain. The animals were monitored, and rectal temperature was measured daily by a
trained veterinarian starting on the day of vaccination and until the end of the trial. A
clinical score from 0 to 6 was assigned according to the clinical status of the animals, as
previously described [20,21]: 0, no signs; 1, mild fever; 2, mild to moderate clinical signs;
3, moderate clinical signs; 4, moderate to severe clinical signs; 5, severe clinical signs; and
6, death. Serum and nasal and rectal swabs were collected on the day of vaccination for
all the groups and at 4, 7, and 14 dpv for groups A and B. Sampling was also carried
out on the day of viral challenge and at 4, 10, and 13 days post-challenge (dpc) for all
the experimental groups. Animals were euthanized before the end of the trial for animal
welfare reasons when they exhibited prostration or reached a clinical score ≥5. At 13 dpc,
the trial was ended and all surviving animals were euthanized and tonsil, spleen, and
mesenteric lymph node were collected. Euthanasia was carried out by a pentobarbital
overdose of 60–100 mg/kg of weight, administered via the jugular vein in accordance
with European Directive. The experiment was conducted in accordance with the existing
Spanish and European regulations and was approved by the Ethical Committee of the
Generalitat de Catalonia, Spain under the animal experimentation project number 10908.
2.3. Determination of IFN-α Levels in Sera by ELISA Test
IFN-α concentration in sera was determined using a previously described in-house
ELISA test [3,22] on the day of vaccination in all groups and at 4, 7, and 14 dpv for groups
A and B. Serum samples were also evaluated on the day of CSFV challenge and at 4, 7, 10,
and 13 dpc in the four experimental groups.
2.4. Evaluation of Humoral Response Against CSFV E2 and Erns Glycoproteins and Neutralising
Antibodies
CSFV E2 specific antibodies were determined in sera samples using a commercial
ELISA kit (IDEXX Laboratories, Liebfeld, Switzerland). The blocking percentage values
were determined following manufacturer’s instruction; values below 30% were considered
as negative, between 30 and 40% were considered doubtful, and above 40% were considered
as positive. Antibodies against the CSFV Erns protein were evaluated using the pigtype©
CSFV Erns Ab test (Qiagen, Leipzig, Germany). Results were calculated by the S/P ratio
(sample/positive control ratio). The S/P values below 0.3 were considered as negative,
between 0.3 and 0.5 were doubtful, and above 0.5 samples were positive.
Furthermore, neutralising antibody response against the Margarita and Alfort/187 strains
was determined by neutralization peroxidase linked assay (NPLA) [23]. Titres were
expressed as the reciprocal dilution of serum that neutralised 100 TCID of 50% of the
culture replicates.
2.5. Detection of CSFV RNA
Viral RNA was extracted from sera, nasal, and rectal swabs and tissue samples using
IndiMag® Pathogen Kit (Indical bioscience, Leipzig, Germany) according to the manufac-
turer’s instructions. Two RT-qPCR assays were used, one for the CSFV RNA detection [24]
and the other for the specific CSFV Margarita strain [20]. Samples were considered negative
when fluorescence was undetectable and positive when the threshold cycle (Ct) values were
equal to or less than 40. The RNA load was defined as high (Ct value below 23), moderate
(Ct values between 23 and 28), or low (Ct value above 28), as previously described [21].
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2.6. Statistical Analysis
The statistical analyses were performed using SPSS software, version 15.0 (SPSS Inc.,
Chicago, IL, USA), and “group” was set as the experimental unit. The non-parametric test
(Kruskal–Wallis) was chosen to compare values obtained from the clinical scores; CSFV
RNA in sera, swabs, and tissues; and IFN-α levels among all experimental groups. The
significance level was set at p < 0.05 throughout the trial.
3. Results
3.1. Thiverval Vaccine Virus Has Weak Replication Capacity and Absence of Transmission
among Pigs
Thiverval strain RNA could not be detected in the majority of the samples during
the 21 dpv (Figure 1). The vaccine virus was unable to generate viremia, shown by the
general lack of viral RNA detection in sera, as only one animal showed low RNA load
(Ct > 35) at four dpv. Likewise, low RNA load in nasal and rectal swabs was sporadically
detected in one pig at 4 dpv and three at 7 dpv, with Ct values above 33. In addition, low or
even absence of vaccine virus RNA load was also detected in the tissue samples from the
euthanized vaccinated pigs at 21 dpv (Ct > 29), (Figure 1). During the 21 dpv, no vaccine
virus RNA was detected in the contact group (group B) and all the animals from both
groups were clinically healthy after vaccination.
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Figure 1. Detection of CSFV RNA load in samples and tissues during 21 days after vaccination. CSFV RNA load was
detected by RT-qPCR and is expressed as Ct values. (-) symbol indicates samples in which fluorescence was not detected.
Grey area indicates that the tissues were not collected at that time, in accordance with the experimental design described in
the Materials and Methods section.
3.2. A Single Vaccine Dose Conferred Early and Solid Protection Against CSFV Challenge at 5 and
21 dpv
Both vaccinated groups showed a total absence of clinical signs after challenge with
a highly virulent CSFV strain with no statistic differences among them (p > 0.05). Thus,
complete protection against CSFV challenge was afforded as early as 5 dpv with a single
dose of the Thiverval strain. By contrast, non-vaccinated, control pigs (group D) started to
show fever, leading to significantly higher clinical score values starting at 2 dpc (p < 0.05),
which increased in the subsequent days, together with clinical signs compatible with severe
acute CSF form (Figure 2). All pigs from this group developed apathy, conjunctivitis,
weakness of the hindquarters, tremors, severe apathy, dyspnoea, and diarrhoea and had
to be euthanized at 7 dpc due to animal welfare. Similar clinical signs were developed by
non-vaccinated pigs from group B (contact of group A), which were statistically different
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from vaccinated groups (A and C) from day 4 until euthanasia (p < 0.05). These animals
were euthanized from 7 to 10 dpc for animal welfare reasons (Figure 2).
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after CSFV “ ar rit str in infection. Animals 2 to 7 (group A) and 14 to 18 (group C) were
challenged after 21 and 5 dpv, r spectively. Animals 8 to 11 (group B), contacts for group A and 19 to
23 (group D), infection control gr up, were not vaccinated but challenged. Pigs were monitored daily
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different letters show statistical difference (p < 0.05).
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3.3. The Thiverval-Strain Vaccine Strongly Activates the Innate Immunity in Pigs
Induction of innate immunity, in terms of IFN-α levels in sera, was detected as early as
4 and 5 dpv with Thiverval strain in groups A and C, respectively. The IFN-α concentration
was significantly higher in both vaccinated groups at this time-point (p < 0.05), reaching
values of >150 units/mL in group C. Values of IFN-α in sera near to 0 units/mL were
found in the majority of unvaccinated pigs from groups B and D (Figure 3).
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3.4. Antibodies Against CSFV E2 and Erns Glycoproteins with Neutralising Activity Are Detected
Two Weeks after Vaccination
E2-specific antibodies were detected at 14 dpv in 5 out of 6 vaccinated pigs from group
A. Subsequently, at 21 dpv (day of CSFV hallenge) the E2 antibody levels in re s in
all vaccinated pigs from group A and blocking percentage va ues were near 100% by the
end of the trial. Antibody response against the E2 glycoprotein was statistically different
between the groups A and B from the 14 dpv onwards (p < 0.05) (Figure 4a).
In the Erns ELISA test, all group A pigs were positive starting at 14 dpv even though
S/P values were highly variable between animals. After CSFV challenge, a sharp increase
in the Erns antibody levels was detected, with similar S/P values for all vaccinated pigs in
group A (values > 3.5). From 14 dpv and until the end of the trial, the antibody response
against Erns glycoprotein was also significantly higher in the vaccinated pigs from group A
than group B (p < 0.05) (Figure 4b).
Accordingl , neutralising ntibodies against Alfort/187 strain were detected starting
at 14 dpv. From 21 dpv, titres were raised against Alfort/187 being above 1:30 in the
majority of group A animals (Figure 5). After Margarita infection, a boost effect was
observed in all vaccinated animals from group A, with titres as high as 1:640 at 13 dpc
against the challenge strain. On the other hand, animals from groups B (contacts) and D
(controls) elicited no neutralising antibody response at any time point during the study
(Figure 5).
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3.5. A single Thiverval Vaccine Dose Conferred Protection Against Viral Replication after CSFV
Challenge at 21 dpv
Notably, after challenge, the absence of viral replication in blood was evidenced by
the lack of CSFV RNA detection in sera samples from all vaccinated animals in group
A (Figure 6a). Moreover, at 10 dpc a low RNA load was detected only in few rectal and
nasal swab samples. However, no CSFV RNA was found in the remaining clinical samples
analysed from vaccinated animals in group A (Figure 6a). Similarly, no viral RNA was
found by either RT-qPCR assay in the spleen samples from group A (Figure 6a,b). Even
though all the tonsil samples were positive for CSFV RNA, only 3 of them were positive
by the Margarita-specific RT-qPCR with significantly lower RNA load (Ct value > 31)
than the unvaccinated groups (p < 0.05). In the case of mesenteric lymph node, low viral
RNA load was found in all the samples by the CSFV specific RT-qPCR (Figure 6a), while
4 out of 6 had Ct values corresponding with low RNA load by the Margarita-specific test
(Figure 6b). Conversely, all the contact and control pigs (groups B and D) were positive in
sera, nasal, and rectal swabs, after CSFV challenge. At 4 dpc, the Ct values corresponded
with moderate and high RNA load by the Margarita-specific assay and were low by the
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CSFV RT-qPCR (Figure 6a,c). Between 7 and 10 dpc (time of euthanasia), the CSFV RNA
load was significantly higher than the vaccinated pigs (p < 0.05), being mostly moderate
by the CSFV RT-qPCR and high in the Margarita-specific test. All the tissue samples from
these groups were positive by both assays, exhibiting mostly high RNA load that was
statistically different (p < 0.05) to the vaccinated pigs (Figure 6 and Figure S1).
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design, see Materials and methods section.
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3.6. Thiverval Vaccine Generates Rapid CSFV Protection at Five Days after Vaccination in the
Absence of Humoral Response
Pigs challenged at 5 dpv (group C) did not show antibody response in terms of E2
and Erns-specific antibodies or neutralising antibodies. Nevertheless, at 4 dpc, one pig
from this group started to show antibodies against the E2 glycoprotein and two of them
had antibodies to Erns (Figure 7a,b). Afterwards, the number of group C animals with
antibodies against both glycoproteins increased at 10 and 13 dpc, with all of them being
positive at the end of the trial. Notably, the antibody response against the E2 and Erns
glycoproteins was statistically different between the groups C and D at 10 dpc (p < 0.05)
(Figure 7a,b).
In terms of neutralising antibodies, titres were detected starting at 10 dpc, with all
group C pigs being positive against Alfort/187 strain and two of them also showing low
titres against Margarita. At 13 dpc, all the pigs from this group had neutralising antibodies
against both viral strains analyzed, with titres being higher against Alfort/187 (between
1:20 and 1:160) than for Margarita (1:20) (Figure 5).
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Figure 7. Kinetic of E2 and Erns antibody response in pigs challenged at 5 dpv and controls (groups C
and D). (a) Antibody response against the E2 glycoprotein was detected by ELISA and is represented
as blocking percentage. (b) Antibody response against Erns was detected by ELISA and reported
as the S/P value in accordance with the formula previously described. Statistically significant
differences between the groups C and D in the antibody response against the E2 (a) and Erns (b)
glycoproteins are represented by the asterisk symbol (*), indicating p < 0.05.
In direct contrast with the viral replication and excretion observed in the control
animals (group D, described above), a complete lack of the CSFV challenge virus RNA was
found in nasal and rectal swabs of the vaccinated pigs after challenge at 5dpv (group C), by
the Margarita-specific test (Figure 6d and Figure S1). Moreover, viremia was nearly absent
in animals from this group, as shown by the low RNA load detected in sera samples at
4 and 10 dpc. The Ct values were around 35.5 in the CSFV-specific test and ranged from
31 to 38 in the Margarita RT-qPCR. No Margarita RNA was detected in sera and swabs
from group C at the end of the trial (13 dpc). Mostly low RNA load was found in the tissue
samples from these pigs by the Margarita strain assay, while in the CSFV-specific test, all
the tonsils showed moderate RNA load and the rest of the positive samples had low or
absent RNA (Figure 6c,d and Figure S1).
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found in sera from the non-vaccinated groups at 4 dpc (p < 0.05). In the control animals
(group D), IFN-α concentration in sera remained high (>180 units/mL) at the time of
euthanasia. Notably, the levels in vaccinated animals were near 0 units/mL (Figure 8).
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Figure 8. IF - levels in sera after challenge during 13 dpc. IFN-α levels were determined at
different time points after challenge with CSFV “Margarita” strain. Asterisk symbol (*) refers to
21 dpv for group A and 5 dpv for group C. Letters above the symbols are used to represent statistically
significant differences between the groups on that day: similar letters indicate no statistical difference,
and different letters show statistical difference (p < 0.05).
4. Discussion
CSF is a re-emerging disease in swine, despite several years of intensive eradication
progra s. s has been explained, the inefficient vaccination programs in some endemic
regions may have contributed to the emergence of new CSFV variants, putatively vaccine
escape t ts, ic t r t the epidemiological surveillance policies [13,25]. Th
reports of th se proposed vaccine escape mutants have mostly come from areas where
vaccination is pe formed wit the C-strain. Notably, in some countries the producti n of
this vaccine is still made in rabbits, mainly due to the p or replication of t cells.
This methodology remains controversial, not only because it constitutes a biosafety and
ethical proble but also due to the inability to predict yield and scale up the production.
Therefore, it is worth noting that other OIE-recommended vaccines, with s able, cell u ture-
bas d pro uction systems, are available.
The present ork ai ed to expand an ate t e i f r ti t t fi , i -
une response, and transmission capacity of the CSFV Thiver al-strain vaccine virus in do-
mestic pigs. In addition, its clini al and virological protection capa ity after CSFV challenge
with a hig ly virulent strain w s ev luated t five and 21 ays fter single vaccination.
The results obtained here demonstrate that the vaccine virus is not transmitted from
vaccinated to contact animals, even after 21 days of close contact in the same pen. This was
shown by the absence of viral R and antibody response detection in the contact ani als.
This is further supported by the fact that this group developed the severe form of CSF after
challenge, evidenced by the progressively worsening clinical signs, the rapid onset of the
IFN-α response, and their inability to generate a CSFV specific antibody response.
Notably, a single dose of Thiverval vaccine can activate the immune response, as
shown by the complete protection from clinical signs afforded in animals that were chal-
lenged either at 5 or 21 dpv, using a severe viral challenge, in accordance with OIE standards.
Moreover, Thiverval vaccine primed the swine immune system to generate CSFV-specific
antibodies against both the E2 and Erns glycoproteins at 14 days after vaccination. These
results are in line with previous findings reported for the C-strain vaccine and the modified
CP7_E2alf vaccine candidate, another well-known alternative for CSFV vaccination [26].
The high levels of E2 and Erns antibodies proved to have neutralising activity that correlated
with robust virological protection detected in the vaccinated animals at 21 dpv. Notably, in
addition to the clinical protection, all of the animals challenged at 21 dpv were protected
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from viremia, supporting the solid neutralising antibody protection conferred after vacci-
nation. Moreover, the Thiverval strain avoided viral shedding by the vaccinated pigs at the
end of the trial. Even though some animals were positive to CSFV RNA detection in swabs
at 10 dpc, in all cases the RNA load was low and no virus was isolated in cell culture [21].
Furthermore, no viral replication was detected in spleen samples from vaccinated pigs,
while in the case of tonsil and mesenteric lymph nodes, the Margarita strain RNA load
detected was mostly low. Probably, the CSFV RNA load in these animals was a result of
the prolonged exposure to a severe CSFV challenge, due to the close interaction between
the vaccinated and contact animals that were secreting high amounts of virus. Considering
that, the Thiverval strain was able to protect the animals not only from the initial challenge
but also from the subsequent “double-challenge” posed by the contacts.
Remarkably, protection was achieved by the Thiverval strain as early as 5 dpv, even in
the absence of antibody response. This suggests the strong activation of cellular immunity
induced by the vaccine strain, which may have been able to control the highly virulent
challenge. Likewise, the rapid and transient activation of innate immunity, in terms of
IFN-α response against CSFV, may explain the solid protection capacity afforded by the
Thiverval vaccine, as well as its efficacy to control viral replication shortly after vaccination.
The antiviral and immunomodulatory effects of type I IFNs, such as IFN-α, have proven
to be very important for impairing viral replication [27]. These results shed light into the
mechanisms that underlie the vaccine protection against CSFV in the absence of specific
humoral response. On the other hand, previous reports have shown that elevated levels
of IFN-α are related to CSF disease severity [28]. In the present study, the vaccine strain
protected the animals against the exacerbated IFN-α response, which was observed in the
control animals. The Thiverval strain, continues to show novel applications, such as its
capacity to protect as early as 5 dpv, that suggest it as an alternative for vaccination in
emergency situations.
5. Conclusions
The Thiverval strain, an OIE-recommended vaccine that was first described decades
ago, conferred solid clinical and virological protection, even against possible reinfection.
Considering its efficacy and rapid protection capacity, this vaccine may be useful for
endemic situations with continuous circulation of virus, as well as for vaccination in
emergency situations. Thus, the Thiverval strain is an attractive vaccine for CSFV control
worldwide, particularly in current endemic situations where new viral escape mutants
may be circulating.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/vaccines9050464/s1, Figure S1: Kinetic of CSFV RNA load detected in all samples from all
experimental groups, collected after viral challenge.
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